Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Emgality galcanezumab Prevention of migraine Reimburse with clinical criteria and/or conditions Complete
Empaveli pegcetacoplan Paroxysmal nocturnal hemoglobinuria Reimburse with clinical criteria and/or conditions Complete
Enablex Darifenacin hydrobromide Bladder, overactive Do not list Complete
Enablex Darifenacin hydrobromide Bladder, overactive List with clinical criteria and/or conditions Complete
Enerzair Breezhaler indacaterol glycopyrronium mometasone furoate Asthma maintenance, adults Reimburse with clinical criteria and/or conditions Complete
Enhertu trastuzumab deruxtecan Metastatic HER2 positive breast cancer Reimburse with clinical criteria and/or conditions Complete
Enhertu trastuzumab deruxtecan Metastatic HER2-positive breast cancer Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. Not filed
Enhertu trastuzumab deruxtecan Gastric or gastroesophageal junction (GEJ) adenocarcinoma Active
Enhertu trastuzumab deruxtecan unresectable or metastatic HER2-low breast cancer Reimburse with clinical criteria and/or conditions Complete
Enspryng satralizumab Neuromyelitis optica spectrum disorder Reimburse with clinical criteria and/or conditions Complete